Covid-19 roundup: Moderna notes higher myocarditis risk for young males when compared to Pfizer's vaccine; EMA signs off on Roche, Celltrion mAb treatments

Zachary Brennan

Senior Editor

Moderna’s new CMO Paul Burton spoke to reporters Thursday morning, attempting to defend his company’s vaccine against questions around heart-related risks that appear to be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Moderna notes higher myocarditis risk for young males when compared to Pfizer's vaccine; EMA signs off on Roche, Celltrion mAb treatments

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Covid-19 roundup: Mod­er­na notes high­er my­ocardi­tis risk for young males when com­pared to Pfiz­er's vac­cine; EMA signs off on Roche, Cell­tri­on mAb treat­ments

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Covid-19 roundup: Moderna notes higher myocarditis risk for young males when compared to Pfizer's vaccine; EMA signs off on Roche, Celltrion mAb treatments